Update
$PDS Biotechnology (PDSB.US)$ Mayank Mamtani’s Buy rating for PDS Biotechnology Corporation is based on a number of significant factors. He highlighted the promising initial immunogenicity data from the ongoing VERSATILE-002 trial of PDS0101 + Keytruda for treating HPV16-positive head & neck squamous cell carcinoma. These findings were supportive of previously impressive results including 27% confirmed overall response rate, median progression-free survival of 8.1 months and an 80% one-year survival rate. It’s worth noting that the survival results from both cohorts are numerically superior compared to first-line and recurring/refractory treatment options as per cross-trial comparisons.![]()
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
